News about Global Pharma

Merck Signs MoU with Siemens to Accelerate Digital Transformation Technology

The MoU makes Siemens a preferred global supplier and strategic partner for Smartfacturing technologies, paving the way for transformative projects across Merck's three business sectors.

Global Pharma | 18/09/2024 | By Aishwarya |  726

Piramal Pharma Gets SBTi Approval for its GHG Emission Reduction Targets

Piramal Pharma Ltd. has committed to reduce absolute scope 1 and 2 GHG emissions 42 percent by FY2030 from a FY2022 base year.

Global Pharma | 17/09/2024 | By Aishwarya |  564

Strides Secures FDA Approval for Fluoxetine Tabs

With the approval of the Fluoxetine Tabs 60 mg strength, the company is now positioned to offer a complete portfolio of Fluoxetine across Capsules and Tablets in 10 mg, 20 mg, and 60 mg strengths.

Global Pharma | 17/09/2024 | By Aishwarya |  662

Lilly Gets FDA Approval for EBGLYSS for Atopic Dermatitis

Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) approved EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.

Global Pharma | 17/09/2024 | By Aishwarya |  835

Zydus Signs Licensing and Supply Agreement with Viwit Pharmaceuticals

As per the terms of the agreement, Viwit will be responsible for ANDA submission, manufacturing and supplying the generic versions of GADAVISTTM and DOTAREM, following the receipt of requisite regulatory approval.

Global Pharma | 16/09/2024 | By Aishwarya |  822

Refeyn Establishes New Mass Photometry Scientific Advisory Board

The new Scientific Advisory Board will convene regularly to explore and evaluate the transformative potential of mass photometry in critical customer workflows.

Global Pharma | 16/09/2024 | By Aishwarya |  787

Arrowhead Pharmaceuticals Secures FDA Breakthrough Therapy Designation for Plozasiran

Arrowhead intends to submit a New Drug Application to the FDA by year-end 2024 and plans to seek regulatory approval with additional global regulatory authorities thereafter.

Global Pharma | 13/09/2024 | By Aishwarya |  565

Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza with ENHANZE

Tecentriq Hybreza can be injected subcutaneously in approximately 7 minutes compared to 30-60 minutes for standard intravenous (IV) infusion of Tecentriq (atezolizumab).

Global Pharma | 13/09/2024 | By Aishwarya |  598

Sunsure Energy to Energise Lupin's Tarapur Facility with 21 MW Solar Power

Through this agreement, Sunsure will supply solar power to Lupin’s Tarapur facility in India, sourced from its 100 MW (150 MWp) solar plant in Solapur.

Global Pharma | 13/09/2024 | By Aishwarya |  841

Varda Works with SSPC to Study Microgravity Crystallization

Varda and SSPC researchers based at the University of Limerick and the Mathematics Applications Consortium for Science and Industry (MACSI), Ireland, are collaborating on research that focuses on developing mathematical models for better understanding of how gravity influences crystallization and the resulting polymorphic outcomes.

Global Pharma | 12/09/2024 | By Aishwarya |  622